
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen Inc. is positioned for significant growth, particularly with its Enhanced Delivery Oligonucleotide platform, which has demonstrated promising preclinical results in the transportation of oligonucleotides across various tissues, addressing severe neuromuscular and neurologic diseases. The company has reported a robust splicing correction rate of 53.7% in its pipeline products, exceeding competitors and suggesting substantial efficacy that could lead to improved muscle performance with repeat dosing. As shares are trading around $4 each, there exists meaningful upside potential contingent upon favorable multi-dose data, which could enhance investor sentiment and reflect the company's emerging value in a competitive market.
Bears say
PepGen Inc. is experiencing a negative outlook primarily due to a recent $1 decrease in its targeted stock price, now set at $8 per share, which reflects concerns over its current market valuation relative to its competitors. Despite having promising data from its DM1 product, the company's market cap remains disproportionately low, suggesting market skepticism regarding its future performance. Moreover, challenges in accessing capital markets could hinder its ability to effectively advance its development pipeline, potentially impacting the execution of its commercial strategies and overall viability.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares